Olga Kordonouri,Felix Reschke,Thomas Danne
Olga Kordonouri
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study [0.03%]
长COVID中新发脂质异常的风险和负担：队列研究
Evan Xu,Yan Xie,Ziyad Al-Aly
Evan Xu
Background: Non-clinical evidence and a few human studies with short follow-ups suggest increased risk of dyslipidaemia in the post-acute phase of COVID-19 (ie, >30 days after SARS-CoV-2 infection). However, detailed larg...
Helen R Murphy
Helen R Murphy
Carmella Evans-Molina,Richard A Oram
Carmella Evans-Molina
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial [0.03%]
孕期胰岛素德谷与胰岛素地特疗效对比（联合门冬胰岛素）治疗1型糖尿病女性患者（EXPECT）：一项开放性，多中心，随机对照非劣效性试验
Elisabeth R Mathiesen,Amra Ciric Alibegovic,Rosa Corcoy et al.
Elisabeth R Mathiesen et al.
Background: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic profile compared with first-generation basal insulins, but there are few data regarding its use...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2023 Feb;11(2):86-95. DOI:10.1016/S2213-8587(22)00307-2 2023
Paul Durrington
Paul Durrington
Molecular basis of normal and pathological puberty: from basic mechanisms to clinical implications [0.03%]
正常和病理性青春期的分子基础：从基本机制到临床影响
Jesús Argente,Leo Dunkel,Ursula B Kaiser et al.
Jesús Argente et al.
Puberty is a major maturational event; its mechanisms and timing are driven by genetic determinants, but also controlled by endogenous and environmental cues. Substantial progress towards elucidation of the neuroendocrine networks governing...
Stephen J Nicholls
Stephen J Nicholls
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial [0.03%]
在具有高心血管风险和升高LDL胆固醇的患者中inclisiran的长期疗效和安全性（ORION-3）：来自ORION -1试验4年开放标签扩展的研究结果
Kausik K Ray,Roel P T Troquay,Frank L J Visseren et al.
Kausik K Ray et al.
Introduction: Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), results in sustained reductions in ...
Controlled Clinical Trial
The lancet. Diabetes & endocrinology. 2023 Feb;11(2):109-119. DOI:10.1016/S2213-8587(22)00353-9 2023
Glucagon, from past to present: a century of intensive research and controversies [0.03%]
从过去到现在，关于 glucagon 一个世纪的深入研究和争议
André J Scheen,Pierre J Lefèbvre
André J Scheen
2022 corresponds to the 100th anniversary of the discovery of glucagon. This TimeCapsule aims to recall the main steps leading to the discovery, characterisation, and clinical importance of the so-called second pancreatic hormone. We descri...